Korro Bio (NASDAQ:KRRO) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Korro Bio (NASDAQ:KRRO) issued its earnings results on Tuesday. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07, Zacks reports. The firm had revenue of $2.27 million for the quarter.

Korro Bio Stock Down 1.9 %

Shares of NASDAQ KRRO opened at $23.72 on Thursday. Korro Bio has a 1 year low of $18.50 and a 1 year high of $98.00. The stock’s 50-day simple moving average is $30.42 and its 200-day simple moving average is $41.70.

Analyst Ratings Changes

Several research firms recently weighed in on KRRO. Oppenheimer started coverage on shares of Korro Bio in a report on Friday, January 10th. They set an “outperform” rating and a $155.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 target price on shares of Korro Bio in a research report on Thursday. Finally, Royal Bank of Canada dropped their target price on Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $142.57.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).